LTRN

Price (1 Year)

Participation Finance Screening Ratios

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.